Drugs / SYH2051
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06011291 | Aug 2023 → Dec 2024 | head and neck cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06775236 | Mar 2025 → Jun 2027 expected | breast cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07104877 | Apr → Nov 2024 overdue | colorectal cancer, gastric cancer | Fujian Cancer Hospital | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-03-13 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYH2051 (SELECTIVE ATM INHIBITOR) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗
The board of directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that SYH2051 (the ‘‘Product ’’) developed by the Group has been approved by the U.S. Food and D rug Administration (FDA) to conduct clinical trials in the U.S. |
| 2023-06-12 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SELECTIVE ATM INHIBITOR SYH2051 OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
SELECTIVE ATM INHIBITOR SYH2051 OBTAINS CLINICAL TRIAL APPROVAL |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-03-13 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYH2051 (SELECTIVE ATM INHIBITOR) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2023-06-12 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SELECTIVE ATM INHIBITOR SYH2051 OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH2051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06011291 ↗ |
| Action | Inhibit | “Selective ATM protein kinase inhibitor” NCT06775236 ↗ |
| Route | Oral | “oral” NCT06775236 ↗ |
| Target | ATM | “Selective ATM protein kinase inhibitor” NCT06775236 ↗ |